1

2 **Polymyxins Nebulization over Intravenous Injection:**

3 Pharmacokinetics and Pharmacodynamics-based Therapeutic

- 4 **Evaluation**
- 5 Abstract
- 6

Polymyxins are the last line potential antibiotics against multi-drug resistant gram-7 8 negative bacteria and consist of two sister antibiotics: polymyxin B and colistin (polymyxin E). Intravenous use of polymyxins was started from a long ago in the 9 treatment of serious gram-negative infections and once their uses were restricted due to 10 11 potential adverse drug reactions, such as nephrotoxicity and neurotoxicity. Lack of in *vivo* clinical studies on polymyxins mostly, in human body makes the pharmacokinetics 12 and pharmacodynamics of polymyxin B and colistin unclear in many aspects, such as 13 the distribution of polymyxins in different compartments of lung. The nebulization of 14 polymyxins is practicing very limitedly and lack of clinical evidence has not justified this 15 administration technique yet properly to date. The main objective of this review study 16 was to evaluate the pharmacokinetic and pharmacodynamic properties of intravenous 17 and nebulized polymyxins and the related therapeutic potentialities. Aerosolized 18 polymyxins directly administered to the respiratory tract was found with higher drug 19 concentration in different subcompartments of lungs than the intravenous administration 20 and sustainably meets the minimum inhibitory concentration locally with superior 21 bactericidal properties in respiratory tract infections. In contrast, intravenous 22 administration of polymyxins shows similar anti-infective superiority in other organs, 23

such as blood, urinary tract etc. So, during this alarming situation of rapidly emerging
multidrug-resistant organisms in human communities, therapeutic administration
techniques of last resort polymyxins should be clinically evidence-based for achieving
optimum therapeutic outcomes with minimum chance of adverse drug reactions.

28

29 Keywords:

30 Polymyxins; Nebulization: Intravenous; Pharmacokinetics; Pharmacodynamics

31

32 1. INTRODUCTION

33

Infections caused by multidrug-resistant (MDR) gram-negative bacteria are considered 34 as a threat for global human health and in most of cases, have c vbeen associated with 35 extremely poor therapeutic outcomes. At present, the emergence of gram-negative 36 bacteria those are capable of producing extended spectrum β-lactamases, metallo-β-37 lactamases and carbapenemase, is the vital alarming issue for the infectious diseases 38 scientists and experts, globally [1]. MDR pathogen, carbapenem-resistance 39 enterobacteriaceae (CRE) is found as the most detrimental gram-negative bacteria in all 40 global human-communities and CRE-associated infections are accompanied with high 41 rated mortality and increased hospital staying-cost, and also the most difficult infections 42 to treat [2, 3]. In the 1940s, a potential polypeptide group of antibiotics, called 43 polymyxins, was discovered, and polymyxin B and colistin (also known as polymyxin E), 44 belongs to polymyxins-group, was initiated to clinically use against those gram-negative 45 bacteria. Intravenous polymyxins were clinically used for at least two decades after its 46

invention. After that, due to the increased number of polymyxins-induced renal and
neuro toxicities, the uses of polymyxins were restricted, globally [4-9].

Among the few last resort potential antibiotics against MDR-CRE, both polymyxin B and 49 are the most prosperous and effective antibiotics. In regards of 50 colistin pharmacokinetics (PK) and pharmacodynamics (PD), intravenous polymyxin B and 51 colistin shows variable characteristics to each other, and controversies are all-around 52 regarding their dosing with limited clinical evidences [4, 6, 10]. The dose versus 53 distribution of intravenous polymyxin B and colistin in respiratory tract is still an 54 unjustified issue, and intravenous form is associated with increased incidences of 55 adverse events [11, 12]. However, in recent years, as a new alternative effective 56 treatment option of MDR-CRE-associated infections, inhalation therapy of polymyxins is 57 found with higher potentiality than intravenous therapy, but the study data is too limited 58 to justify [13, 14]. The main objective of this review study is to evaluate the latest clinical 59 outcomes of nebulization therapy of polymyxin B and colistin considering their PK and 60 PD properties. 61

62

63 2. STRUCTURE, MECHANISM OF ACTION AND SPECTRUM OF ACTIVITY


64

Polymyxins are cationic polypeptides that contain a cyclic heptapeptide having a tripeptide side chain where N terminus is completely acylated by a fatty acid tail [10]. Amino acid components in the peptide chain basically differentiate between polymyxin B and colistin. L-threonine and L- $\alpha\gamma$ -diaminobutyric acid (Dab) is common in both

antibiotics but, the only difference is that polymyxin B contains D-phenylalanine 69 whereas, in the same position, colistin possesses D-leucine [1, 10]. 70

Polymyxin B is the active form of drug and administered directly while colistin is the bio-71 active form an inactive prodrug, colistimethate Sodium (CMS) [10]. Polymyxins increase 72 cell membrane's permeability of the gram-negative bacteria by displacing Ca²⁺ and 73 Mq^{2+} from PO_4^{3-} of the bacterial cell membrane through an electrostatic interaction 74 between α y-Dab⁺ of polymyxins and PO₄³⁻ of the bacterial cell membrane, and finally, 75 bacterial cell death takes place (Fig. 1) [1, 10]. 76

- 77
- 78



80

81 Polymyxins have narrow spectrum bactericidal property against common gram-negative prominent activity is found against the 82 bacteria and most members of Enterobacteriaceae family, such as Escherichia coli, Klebsiella spp., Pseudomonas 83 aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia. Some gram-84 negative bacteria are naturally resistant to polymyxins like, Serratia marcescens, 85 Proteus spp., Burkholderia cepacia, Morganella morganii, Campylobacter, Providencia 86 spp., Brucella, Legionella, Edwardsiella spp. and Vibrio cholera [10, 15]. 87

88

89

90 **3. DOSING: IV Injection and Nebulization**

91

Polymyxin B is commercially available as intravenous polymyxin B sulfate and colistin 92 has to commercial forms; colistimethate sodium (CMS) is intravenously used while 93 colistin sulfate is used topically or orally [1]. The commercial package of polymyxin B 94 expresses its strength in International Unit (IU) and 10,000 IU is equal to 1 milligram of 95 polymyxin B. In healthy renal function, the recommended intravenous daily dose of 96 polymyxin B is 15,000-25,000 IU/kg of body weight (BW) (1.5-2.5 mg/kg of BW) divided 97 into 2 equal doses for adults and children older than 2 years. Standard dose adjustment 98 guideline either in renal impaired patient or in patient with intermittent hemodialysis or 99 100 continuous venovenous haemo(dia)filtration (CVVHF, CVVHDF) has not yet been established [16]. As a prodrug, CMS is commercially available in million and milligram, 101 but after intravenous administration, CMS is converted in the biological system to 102 103 colistin base activity (CBA) which is the pharmacologically active form (conversion: 1

104 million international unit CMS = 80 mg CMS = 33 mg CBA). For resolving the dosing conflicts of CMS, 'Million International Unit' (MIU) is the globally most preferred unit of 105 expression [17-19]. The usual daily recommended dose of intravenous CBA is 75-600 106 107 mg (through intravenous route in the form of CMS) and alternatively, 2.5-5 mg/Kg of BW divided into 2 to 4 equal doses [19, 20]. Dose adjustment is recommended in renal 108 impairment. As per the practice guidelines in United States (US), in serious gram-109 negative bacterial infections in adults and children, CMS 2 MIU in every 12 hours, 24 110 hours and 36 hours is recommended in serum creatinine level 1.3-1.5 mg/dL, 1.6-2.5 111 mg/dL and \geq 2.6 mg/dL, respectively [1, 20]. In the United Kingdom (UK), the daily 112 dosing regimen of CMS has been upgraded to 4-6 mg/Kg of BW (50,000-75,000 IU/kg 113 of BW) divided into 3 equal doses, in adult and children with normal renal function [20, 114 21]. Colistin is significantly removed during intermittent hemodialysis and supplementary 115 dosing of CMS is required after each dialysis session to maintain steady serum CBA 116 concentration [20, 21]. 117

118

Direct administration of polymyxins in gram-negative bacteria-associated respiratory 119 tract infections (RTI) is restricted, such as colistin nebulization in patients with cystic 120 fibrosis [10]. The aerosolized dosing regimen of polymyxin B and colistin has not yet 121 been globally established and in some places, recently this drug delivery system has 122 123 been introduced as a secondary administrative option for treating serious infections of RTI. Due to the lack of PK/PD data on aerosolized polymyxin B, no specific dosing 124 regimen has yet been developed [23]. In a 18-month long ICU-based study, researchers 125 126 found that polymyxin B nebulization in 2 mg/Kg of BW/ day in 2 equally divided doses

showed promising therapeutic outcomes [13]. In the UK, the recommended aerosolized dosing regimen of CMS is 500,000 units (40 mg CMS) every 12 hours for patients with a BW \leq 40 kg and for a BW >40 kg, the dose is 1 MIU (80 mg CMS) every 12 hours. The highest recommended dose is 2 million units (160 mg CMS) every 8 hours, especially in recurrent severe RTI [1, 22].

- 132
- 133
- 134
- 135

136 4. PHARMACOKINETICS: IV INJECTION AND NEBULIZATION

137

The pharmacokinetics of polymyxins is not clearly understood to date with limited 138 number of clinical studies. One study included 8 critically ill patients and found that <1% 139 of administered polymyxin B is excreted through urine as unchanged form and the 140 major portion of the dose is extensively reabsorbed from the renal tubules, and 141 eliminated through non-renal pathway [24]. Thus, limited renal function does not affect 142 the serum steady state concentration (C_{ss}) of polymyxin B [10]. Another study was 143 conducted on 24 critically ill patients with mild to severe renal impairment (CL_{Cr}= 10-144 143 mL/min). Intravenous polymyxin B dose was given as 0.45 mg/kg of BW/day - 3.38 145 146 mg/kg of BW/day and researchers estimated the C_{ss.avg} was 0.68 mg/L - 4.88 mg/L and only 4.04% (median value) was recovered in urine [25]. That study included 2 patients 147 with continuous renal replacement therapy (CRRT) where 5.62% and 12.2% of the 148 administered dose was removed as dialysate during the dialysis [25]. Hence, 149

150 supplementary dosing of polymyxin B is required for patients with CRRT but, lack of specific clinical study, the supplementary dose of polymyxin B has not yet been 151 established [25, 26]. Following the intravenous administration of CMS, the major portion 152 of CMS is eliminated by kidneys and high concentration of CMS becomes available in 153 urine [27]. Only 20-25% of a CMS dose is hydrolyzed into active colistin before it 154 passing through glomerulus and renal tubules and a relatively smaller fraction of total 155 CMS dose is found in the system to provide its antibacterial action [28]. This colistin is 156 extensively reabsorbed in the renal tubules and eliminated predominantly through the 157 non-renal pathway [10]. During passing through the urinary tract, CMS is also converted 158 to colistin, reabsorbed and negligible amount is excreted by urine [28]. Thus, it is difficult 159 to achieve a C_{ss.avg} of 1 mg/L in healthy renal patient followed by a usual CMS dosing 160 161 [29]. Due to excessive removal of CMS during from body during hemodialysis, a supplementary dose 1.7 million IU of CMS is required to replenish the loss [26]. 162

The distribution of polymyxin B in extravascular sites following intravenous 163 administration is little known due to lack of in vivo studies. A study was conducted on 164 Sprague-Dawley rats and analyzed the different tissue concentrations followed by an 165 intravenous polymyxin B dose of 3 mg/kg of BW. Highest polymyxin B concentration 166 was detected in the proximal renal tubular cells. Higher concentration was also found in 167 lung tissue than the serum at 6 h but, variable drug-distribution pattern was observed in 168 169 different subcompartments of lung, such as lung parenchyma, alveolar epithelium, epithelial lining fluid and so on [30]. A study found that followed by a usual intravenous 170 dose of CMS, a minimal level of colistin is found in sputum in patients with cystic fibrosis 171 172 (CF). The penetration of colistin in the central nervous system through blood-brain barrier is very poor (approximately 5%) [31], and during meningitis and inflammation, it
ranges from 25% to 67% [32, 33] and even no concentration detected [34]. Distribution
of colistin to biliary tract, different joint fluids and pleural fluid is also poor [35]. A study
on 13 critically ill patients found that suboptimal serum concentration and undetectable
concentration of colistin in bronchoalveoalar lavage fluid is attained followed by
intravenous 480 mg CMS/day [36].

Polymyxins nebulization is a new technique of delivering aerosolized polymyxins directly 179 at the site of infection specially, in the respiratory tract. Lack of dependable 180 pharmacokinetic and pharmacodynamic data basically makes this method to date 181 unpopular [26]. The first clinical evidence of aerosolized polymyxin B administration 182 directly to the respiratory tract was recorded in 1695. In that case study, recurrent 183 184 presence of *Pseudomonas aeruginosa* in the sputum after treating with intravenous polymyxin B, aerosolized polymyxin B was administered directly with few therapeutic 185 success [37]. A study was conducted to analyze the pharmacokinetics and 186 pharmacodynamics of aerosolized polymyxin B in neutropenic mouse lung infection 187 model (infected with Pseudomonas aeruginosa), after inhaling polymyxin B (dose: 4.12 188 and 8.24 mg base/kg of BW; volume of 25 µL). The post 24-hour histopathological 189 analysis found a comprehensive result in the reduction of infection (AUC/MIC: $R^2 = 0.70$ 190 to 0.88) in lung of mice and that included lung epithelial integrity. The same study also 191 192 showed effective PK/PD characteristics attained by polymyxin B nebulization and achieved relatively higher drug concentration than intravenous polymyxin B [23]. The 193 concentration of polymyxin B is affected by the route of administration and relatively 194 195 higher concentration is attained by inhaling polymyxin B in mice [23].

196 Similar kind of advantageous results were found with colistin nebulization in MDR gramnegative pathogens-associated RTIs. A study on 21 patients found 85.7% 197 microbiological response and 57.1% therapeutic response when nebulized colistin was 198 applied against MDR Acinetobacter baumannii and Pseudomonas aeruginosa-199 associated pneumonia [14]. A recent study found that the concentration of colistin in 200 sputum of patients with CF is minimally followed by intravenous CMS administration. 201 When aerosolized colistin was administered, a >10-fold higher concentration (dose of 202 CMS: 4 MIU/day) of colistin was found in sputum [38]. In a rat PK study, 23-39% of the 203 pulmonary administered CMS dose was converted to active colistin in the rat lung [39]. 204 This CMS to colistin conversion is a slow process and the highest concentration of 205 colistin achieved after 1 to 5 hours of CMS nebulization in patient with CF [38]. 206 207 However, few specific clinical studies are required at this moment to understand the real therapeutic and microbiological outcomes of polymyxins nebulization in patients with 208 MDR gram-negative bacteria-associated RTIs. 209

210

5. PHARMACODYNAMICS: IV INJECTION AND NEBULIZATION

212

Colistin is widely used in several clinical studies for analyzing the overall pharmacodynamic properties of polymyxins including polymyxin B [26, 40-42]. Multiple *in vitro* studies showed that colistin possesses a rapid concentration-dependent killing property against the MDR gram-negative bacteria and a short post-antibiotic effect followed by achieving even maximum serum colistin concentration [40-42]. *A. baumannii, K. pneumonia and p. aeruginosa* are the furious resistance developing

organisms, and both polymyxin B and colistin shows a rapid killing phenomenon against 219 these organisms but a rapid re-growth property is observed in these organisms [43-45]. 220 In neutropenic mouse thigh and lung infection models, the antibacterial property of 221 222 colistin against A. baumannii and P. aeruginosa is predicted nicely by using PK-PD index which is the ratio of the area under the unbound (free) drug concentration-time 223 curve at 0-24 hours to the MIC (minimum inhibitory concentration) (fAUC₀₋₂₄/MIC); 224 considering the PK/PD index which is superior to the maximum serum drug 225 concentration (C_{max})/MIC relationship, it is suggested that time versus colistin exposure 226 in the serum is more effective than achieving a maximum (peak) serum colistin 227 concentration [10, 26, 46]. To maximize the killing ability of colistin, the average steady-228 state plasma colistin concentration should be maintained at 2 µg/mL [47]. 229 230 Heteroresistance of MDR K. pneumonia [48], P. aeruginosa [49] and A. baumannii was found against colistin in 23-100% of clinical isolates [50, 51]. 231

Most of the clinical studies were associated with intravenous polymyxins administration 232 and pharmacodynamic properties of polymyxins are mostly based on those clinical data. 233 The use of colistin nebulization in patients with *P. aeruginosa*-associated CF is an 234 oldest practice [52, 53]. A study on neutropenic infected mice showed that nebulized 235 polymyxin B increases the total exposure time and this extended pulmonary exposure of 236 polymyxin B is maintained above the resistance breakpoints >2 mg/L over 12-hour 237 238 against P. aeruginosa and A. baumannii [54]. The strong molecular binding of polymyxin B to the alveolar macrophages [55] and the alveolar basement membrane is the main 239 240 fact behind the longer retention time of polymyxin B in epithelial lining fluid (ELF) [56].

Same prolonged and extensive retention of colistin was observed in studies on sheep,
rats, and mice [57-59].

243

244 6. NEBULIZATION VERSUS IV INJECTION: THERAPEUTIC OUTCOMES AND 245 SAFETY

246

Experience with intravenous polymyxins mostly, with colistin to date is abundant but, 247 very negligible with polymyxins nebulization. A cohort study was experienced with 248 significantly inferior clinical response (25%) when 60 patients of that study were treated 249 with intravenous colistin for treating pneumonia associated with MDR P. aeruginosa and 250 A. baumannii [60]. The main reason behind that less favorable outcome in that study 251 252 was the intravenous administration of colistin which might be responsible for inadequate achieved concentration of colistin in ELF of the pulmonary parenchyma [60]. Some 253 similar kind of studies found anecdotal clinical outcomes with colistin nebulization in 3 254 patients [61] and 8 patients [62]. Furthermore, renal dysfunction is the most frequently 255 experienced adverse event associated with intravenous colistin therapy in usual doses 256 [14, 60]. Another study with 21 patients suffering from MDR A. baumannii and P. 257 aeruginosa strains-associated pneumonia was experienced with favorable clinical 258 outcome (85.7%) and no renal dysfunction, significantly with the nebulization therapy of 259 colistin [14]. A recent clinical study on 60 patients with pneumonia treated with 260 intravenous polymyxin B in combination therapy, showed 20% mortality and 88% cure 261 rate [63]. Only one study was conducted to evaluate the PK/PD of polymyxin B 262 263 administration in intravenous (dose: 2 mg/Kg) versus nebulization (dose: 2 mg/Kg)

264 route, in MDR pneumonia patients. That study found superior clinical outcomes in terms of disease improvement, cure and failure rates, with polymyxin B nebulization (44%, 265 44% and 12%, respectively) in comparison to intravenous administration (40%, 20% 266 and 40%, respectively) [13]. Multiple studies found 16% (bronchospasm) [13] and 21% 267 adverse event when aerosolized polymyxin B was administered [64]. Study showed 268 nephrotoxicity occurred 28% with intravenous administration while no adverse event 269 was recorded against nebulization of polymyxin B [13]. Critically ill patients in ICU, 270 commonly suffer from multiple drug-associated nephrotoxicity those are difficult to 271 detect and intravenous polymyxins may aggravate this possibility [13]. Polymyxin B 272 nebulization therapy reduces the overall hospital staying time (28.68±9.15) more than 273 intravenous therapy (31.64±9.16) (p-value: 0.258786) [13]. Although, both the PK and 274 275 PD of inhaled polymyxins are not clearly defined till to date in the human body, however, the overall clinical outcomes mostly based on animal models, have made a 276 scope of reliability on polymyxins nebulization for treating RTI mostly, pneumonia with 277 MDR gram-negative bacteria, during this emergency, in association with less chance of 278 adverse events in critically ill patients. Soon, some reliable clinical studies are required 279 specifically in this field to clearly determine the PK and PD of nebulized polymyxins in 280 the human. 281

282

283 7. CONCLUSION

284

Polymyxins are the last line treatment option for serious infections with MDR gramnegative bacteria and lack of potential antibiotics in this line, polymyxins should be used

- rationally and effectively to obtain the maximum clinical benefits from the therapy. Use
- of polymyxins nebulization in RTIs is such a way that turn off the IV route and optimizes
- the overall therapeutic outcomes and reduces direct IV route-associated adverse events
- 290 during this MDR pathogenic emergency.
- 291
- 292

293 COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

300 Ethical Approval: NA

301

302 CONSENT

- 303 It is not applicable.
- 304
- 305
- 306 FUNDING
- 307 No funding sources.
- 308
- 309 References
- 310
- 1. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The Use of Intravenous
- and Aerosolized Polymyxins for the Treatment of Infections in Critically III Patients: A
- Review of the Recent Literature. Clin Med Res. 2006;4:138-46.
- 2. Gupta S, Govil D, Kakar PN, Prakash O, Arora D, Das S, Govil P, Malhotra A.
- Colistin and polymyxin B: a re-emergence. Indian J Crit Care Med. 2009;13:49-53.

- 316 3. Venkatachalam I, Teo J, Balm MND, Fisher DA, Jureen R, Lin RTP. Klebsiella
- 317 pneumoniae Carbapenemase-producing Enterobacteria in Hospital, Singapore.
- 318 Emerg Infect Dis. 2012;18:1381–1383.
- 4. Fekety FRJr, Norman PS, Cluff LE. The treatment of gram-negative bacillary
- infections with colistin. The toxicity and efficacy of large doses in forty-eight patients.
- 321 Ann Intern Med. 1962;57:214-229.
- 5. Koyama Y, Kurosasa A, Tsuchiya A, Takakuta K. A new antibiotic "colistin" produced
 by spore-forming soil bacteria. J Antibiot. 1950;3:457-458.
- 324 6. Nord NM, Hoeprich PD. Polymyxin B and colistin. A critical comparison. N Engl J
- 325 Med. 1964;270:1030-1035.
- 326 7. Yow EM, Tan E, Shane L, Schonfeld S, Abu-Nassar H. Colistin (coly-mycin) in
- resistant bacterial infections. A clinical appraisal. Arch Intern Med. 1961;108:664-
- 328 **670**.
- 329 8. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse
- effects of sodium colistimethate. Manifestations and specific reaction rates during
- 331 317 courses of therapy. Ann Intern Med. 1970;72:857-868.
- 332 9. Tallgren LG, Liewendahl K, Kuhlbaeck B. The therapeutic success and
- nephrotoxicity of colistin in acute and chronic nephropathies with impaired renal
- function. Acta Med Scand. 1965;177:717-728.
- 10. Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility
- testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin
- 337 Microbiol Rev. 2017;30:557–596.
- 11. Livermore DM. The need for new antibiotics. Clin Microbiol Infect. 2004;10:1-9.

339	12. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for
340	emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999;33:960-
341	967.
342	13. Konkyana SK, Akkenapalli AK. Treatment of multi drug resistant gram negative
343	bacilli with inhaled polymyxin-b. Asian Pac J Health Sci. 2016;3:135-141.
344	14. Kwa ALH, Loh CS, Low JGH, Kurup A, Tam VH. Nebulized colistin in the treatment
345	of pneumonia due to multidrug-resistant Acinetobacter baumannii and
346	Pseudomonas aeruginosa. Clin Infect Dis. 2005;41:754-757.
347	15. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial
348	susceptibility testing methods for polymyxin B and colistin: review of available
349	interpretative criteria and quality control guidelines. J Clin Microbiol. 2001;39:183-
350	190.
351	16. Polymyxin B for Injection USP[package insert]. SteriMax Inc., 2770 Portland Drive,
352	Oakville, Ontario, L6H 6R4, 2016. Available at: http://sterimaxinc.com/wp-
353	content/uploads/2016/03/1.3.1-SteriMax-English-PM-February-8-201612.pdf
354	17. Colistimethate Sodium dry-filled vials [package insert]. Xellia Pharmaceuticals ApS,
355	Copenhagen, Denmark, 2018. Available at: https://www.xellia.com/us/-
356	/media/xellia/products/colistimethate-(1)/october/cms-package-insert.pdf
357	18. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL,
358	Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. Consistent global approach on
359	reporting of colistin doses to promote safe and effective use. Clin Infect Dis.
360	2014;58:139 –141.

Page 16

- 19. Theuretzbacher U. Product information for parenteral colistin varies substantially
 across Europe. J Antimicrob Chemother. 2014;69:1987–1992.
- 363 20. Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A,
- Paterson DL, Li J, Silveira FP. Dosing Guidance for Intravenous Colistin in Critically
- 365 Ill Patients. Clin Infect Dis. 2017;64:565–571.
- 21. Marchand S, Frat JP, Petitpas F, Lemaître F, Gobin P, Robert R, Mimoz O, Couet
- W. Removal of colistin during intermittent haemodialysis in two critically ill patients. J
 Antimicrob Chemother. 2010;65:1836-1837.
- 22. West Sussex, UK: Profile Pharma Limited, UK. Promixin 1 MIU powder for nebuliser
- solution. Package insert, 2003.
- 23. Lin YW, Zhou Q, Onufrak NJ, Wirth V, Chen K, Wang J, Forrest A, Chan HK, Li J.
- Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections:
- 373 Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized
- Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
- Antimicrob Agents Chemother. 2017;61:e00211-17.
- 376 24. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of
- 377 multidrug-resistant pathogens: a critical review. J Antimicrob Chemother.
- 378 2007;60:1206-1215.
- 25. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle
- 380 TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. Population
- 381 pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for
- selection of dosage regimens. Clin Infect Dis. 2013;57:524-531.

- 26. Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, Li J.
- 384 Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

385 Int J Antimicrob Agents. 2016;48:592-597.

- 27. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K.
- 387 Pharmacokinetics of colistin methanesulphonate and colistin in rats following an
- intravenous dose of colistin methanesulphonate. J Antimicrob Chemother.
- 389 2004;53:837-840.
- 28. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and
- 391 cheese? Clin Infect Dis. 2014;59:88-94.
- 392 29. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP,
- 393 Forrest A, Nation RL. Population pharmacokinetics of colistin methanesulfonate and
- 394 formed colistin in critically ill patients from a multicenter study provide dosing
- 395 suggestions for various categories of patients. Antimicrob Agents Chemother.
- 396 2011;55:3284–3294.
- 397 30. Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS, Eriksen JL, Tam VH.
- 398 Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model.
- Antimicrob Agents Chemother. 2015;60:1029-34.
- 400 31. Markantonis SL, Markou N, Fousteri M, Sakellaridis N, Karatzas S, Alamanos I,
- Dimopoulou E, Baltopoulos G. Penetration of colistin into cerebrospinal fluid.
- 402 Antimicrob Agents Chemother. 2009;53:4907-4910.
- 403 32. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, Martin-Lozano D,
- 404 Prados T, Pachon J. Cerebrospinal fluid penetration and
- 405 pharmacokinetic/pharmacodynamic parameters of intravenously administered

- 406 colistin in a case of multidrug-resistant *Acinetobacter baumannii* meningitis. Eur J
 407 Clin Microbiol Infect Dis. 2002;21:212-214.
- 408 33. Antachopoulos C, Karvanen M, Iosifidis E, Jansson B, Plachouras D, Cars O,
- 409 Roilides E. Serum and cerebrospinal fluid levels of colistin in pediatric patients.
- 410 Antimicrob Agents Chemother. 2010;54:3985-3987.
- 34. Everett ED, Strausbaugh LJ. Antimicrobial agents and the central nervous system.
 Neurosurgery 1980;6:691-714.
- 413 35. Mandell G, Bennett J, Dolin R. Principles and practice of infectious diseases, 7th
- 414 edn., Churchill Livingstone Elsevier, Philadelphia, PA, 2010.
- 36. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. Steady-
- 416 state pharmacokinetics and BAL concentration of colistin in critically ill patients after
- 417 IV colistin methanesulfonate administration. Chest 2010;138:1333-1339.
- 37. Marschke G, Sarauw A. Polymyxin inhalation therapeutic hazard. Ann Intern Med.
 1971;74:144–145.
- 420 38. Yapa WS, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S,
- 421 Williams E, Porter CJ, Nation RL, McIntosh MP. Pulmonary and systemic
- 422 pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic
- 423 fibrosis patients: targeting advantage of inhalational administration. Antimicrob
- 424 Agents Chemother. 2014;58:2570–2579.
- 425 39. Yapa WS, Li J, Porter CJ, Nation RL, Patel K, McIntosh MP. Population
- 426 pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung
- 427 concentrations of colistin for targeting respiratory infections. Antimicrob Agents
- 428 Chemother. 2013;57:5087–5095.

429	40. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against
430	Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007;59:473-
431	477.
432	41. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J. In
433	vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella
434	pneumoniae. J Antimicrob Chemother. 2008;62:1311–1318.
435	42. Bergen PJ, Bulitta JB, Forrest A, Tsuji BT, Li J, Nation RL.
436	Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas
437	aeruginosa using an in vitro model. Antimicrob Agents Chemother. 2010;54:3783-
438	3789.
439	43. Tran TB, Cheah SE, Yu HH, Bergen PJ, Nation RL, Creek DJ, Purcell A, Forrest A,
440	Doi Y, Song J, Velkov T, Li J. Anthelmintic closantel enhances bacterial killing of
441	polymyxin B against multidrug-resistant Acinetobacter baumannii. J Antibiot (Tokyo).
442	2016;69:415–421.
443	44. Abdul Rahim N, Cheah SE, Johnson MD, Yu H, Sidjabat HE, Boyce J, Butler MS,
444	Cooper MA, Fu J, Paterson DL, Nation RL, Bergen PJ, Velkov T, Li J. Synergistic
445	killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics—
446	polymyxin B and chloramphenicol. J Antimicrob Chemother. 2015;70:2589–2597.
447	45. Tam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE.
448	Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob
449	Agents Chemother. 2005;49:3624–3630.
450	46. Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL. New
451	pharmacokinetic/pharmacodynamic studies of systemically administered colistin

452	against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and
453	lung infection models: smaller response in lung infection. J Antimicrob Chemother.
454	2015;70:3291-3297.
455	47. Landersdorfer CB, Nation RL. Colistin: how should it be dosed for the critically ill?
456	Semin Respir Crit Care Med. 2015;36:126 -135.
457	48. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. Colistin heteroresistance
458	in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother.
459	2011;66:946–947.
460	49. Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, Li J, Nation
461	RL. Clinically relevant plasma concentrations of colistin in combination with
462	imipenem enhance pharmacodynamic activity against multidrug-resistant
463	Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother.
464	2011;55:5134–5142.
465	50. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L.
466	Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.
467	Antimicrob Agents Chemother. 2006;50:2946–2950.
468	51. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter
469	and its association with previous colistin therapy. Antimicrob Agents Chemother.
470	2008;52:351–352.
471	52. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Hoiby N. Spread of colistin
472	resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish
473	cystic fibrosis patients. J Cyst Fibro. 2008;7:391–397.

Page 21

- 53. Sun HY, Fujitani S, Quintiliani R, Yu VL. Pneumonia due to Pseudomonas
- 475 aeruginosa: Part II: Antimicrobial resistance, pharmacodynamic concepts, and

476 antibiotic therapy. Chest 2011;139:1172–1185.

- 477 54. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B
- 478 against a worldwide collection of Gram-negative pathogens: results from the
- 479 SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother.

480 2011;66:2070–2074.

- 481 55. Bysani GK, Stokes DC, Fishman M, Shenep JL, Hildner WK, Rufus K, Bradham N,
- 482 Costlow ME. Binding of polymyxin B to rat alveolar macrophages. J Infect Dis.

483 1990;162:939–943.

484 56. Brody JS, Vaccaro CA, Hill NS, Rounds S. Binding of charged ferritin to alveolar wall
 485 components and charge selectivity of macromolecular transport in permeability

486 pulmonary edema in rats. Circ Res. 1984;55:155–167.

487 57. Landersdorfer CB, Nguyen T-H, Lieu LT, Nguyen G, Bischof RJ, Meeusen EN, Li J,

488 Nation RL, McIntosh MP. Substantial targeting advantage achieved by pulmonary

- 489 administration of colistin methanesulfonate in a large-animal model. Antimicrob
- 490 Agents Chemother. 2017;61:e01934-16.
- 491 58. Yapa SW. Ph.D. thesis. Monash University, Melbourne, Victoria, Australia, 2013.
- 492 59. Lin Y-W, Zhou Q, Cheah S-E, Zhao J, Chen K, Wang J, Chan H-K, Li J.
- 493 Pharmacokinetics/pharmacodynamics of pulmonary delivery of colistin against
- 494 Pseudomonas aeruginosa in a mouse lung infection model. Antimicrob Agents
- 495 Chemother. 2017;61:e02025-16.

496	60. Levin AS, Barone AA, Penco J, Santos MV, Marinho IS, Arruda EA, Manrique EI,
497	Costa SF. Intravenous colistin as therapy for nosocomial infections caused by
498	multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin
499	Infect Dis. 1999;28:1008–1011.
500	61. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by
501	multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir
502	Crit Care Med. 2000;162:328–330.
503	62. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME.
504	Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-
505	resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care.
506	2005;9:R53–59.
507	63. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and
508	efficacy against nosocomial infections caused by multiresistant gram-negative
509	bacteria. Antimicrob Agents Chemother. 2003;47:2659-2662.
510	64. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial
511	treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli
512	with inhaled polymyxin B. Diagn Microbiol Infect Dis. 2007;58:235-240.
513	